Participated · Series C · Dec 2025

AITRICS is a Seoul-based medical AI company founded in 2017 that develops software to assist clinicians with real-time decision making and operational efficiency. Its flagship platforms, AITRICS-VC (VitalCare) and V.Doc Pro, analyze patient data to predict clinical deterioration and guide treatment. The firm has expanded internationally with subsidiaries in Japan and the United States. Fresh capital will be directed toward enhancing these core products, advancing new R&D pipelines, and growing sales operations across Asia and North America. Since inception the company has raised a cumulative ₩73.1 billion (≈ $55 million) in venture funding, including the newly announced Series C. No revenue or user figures were disclosed in the article, but management positions the offering as a critical tool for improving patient outcomes and hospital efficiency.

Participated · Series B · Oct 2025

DSRV Labs delivers core infrastructure that secures and enables participation in over 70 proof-of-stake blockchain networks, running thousands of validator nodes for institutional and enterprise clients. Its product suite spans staking-as-a-service, custody, APIs, wallet and RPC services, all designed to make Web3 interaction simple, secure, and scalable. The company has more than four years of operating history and has emerged as one of Asia’s most active infrastructure partners for major Web3 ecosystems. Newly raised capital will fund the build-out of multi-chain stablecoin and payment rails aimed at remittances, settlements, and cross-border transactions. DSRV also plans to deepen its staking offerings, hire additional blockchain and compliance talent, and accelerate geographic expansion into the United States, Japan, and Africa. Including the latest financing, the firm’s Series B totals roughly 30 billion KRW ($22.5 million), underscoring growing institutional confidence in its roadmap.

Led · Series B · Jun 2025

Founded in May 2019, Flex provides a unified HR-tech platform that automates employee and organization management, attendance tracking, electronic contracts, payroll, workflows, analytics, performance reviews, recruitment, and finance functions such as expense management and year-end settlement. The software is underpinned by artificial intelligence to streamline administrative tasks and surface strategic workforce insights. Flex positions itself as a next-generation “SaaS 2.0” provider and intends to expand its feature set with additional AI-driven services. The company is also preparing for global expansion beyond its core South Korean market. Proceeds from recent financings will be directed toward scaling engineering and sales teams and adding senior leadership talent. Including the latest bridge round, Flex has raised roughly ₩80 billion (about US$58 million) to date, although specific revenue or user metrics have not been disclosed.

Participated · Series A · Jul 2024

Gcore provides edge AI, cloud, network, and security solutions and serves public organizations, telcos, and global corporations across media and entertainment, gaming, technology, financial services, and retail. The company operates a global IT infrastructure across six continents with over 180 edge nodes/points of presence, 25+ cloud locations, a total network capacity exceeding 200 Tbps, and an average response time of 30 ms worldwide. Gcore employs a team of 600 across ten offices and has delivered cloud capabilities for AI training and inference, including support for large language model training and edge inference. Built for the edge and addressing a $200bn+ market opportunity, the company emphasizes low latency, data sovereignty, and efficient cloud resource utilization. Gcore plans to invest its new funding into its technology and platform—specifically expanding AI servers powered by NVIDIA GPUs—and to enhance its edge AI offerings and global infrastructure.

Participated · Series A · Dec 2023

ImpriMed develops AI-powered live-cell drug sensitivity and predictive models to identify effective anticancer medicines for individual canine and feline blood cancers. Its core service measures live tumor-cell responses in a California lab and combines those measurements with biological data to produce a treatment report delivered to veterinarians within seven days. Veterinary services are fully commercialized (five canine and three feline services), generate revenue, and have been used by more than 350 U.S. veterinarians; the company says it has helped over 5,000 dogs with lymphoma and collected outcome follow-up on over half of those cases. ImpriMed has run validation work with data from 2,000 human blood-cancer patients and the Mayo Clinic Platform’s 3 million‑patient database. The company plans to expand its veterinary-to-human precision oncology efforts, with an AI multiple myeloma product targeting commercialization in 2025 and plans to commercialize services for human AML and non-Hodgkin’s lymphoma before the end of 2024. It also offers a live-cell CRO service to help drug developers measure compound efficacy on patient cells. The startup plans to use new funding to expand its drug-response prediction technology into human oncology, grow its team (about 40 staff) and broaden business-development pipelines. ImpriMed is a Palo Alto-based veterinary precision medicine company that uses artificial intelligence to predict which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia. It generates live data from chemosensitivity and immunophenotyping assays on patients’ fresh cancer cells to produce quantified drug response predictions for veterinary oncologists. Led by CEO and co‑founder Dr. Sungwon Lim, the company enables clinicians to make chemotherapy decisions with greater confidence prior to drug administration. To date ImpriMed has provided more than 2,000 services to community-treated canine patients. The company plans to use the new funding to develop additional prediction models for its current canine blood-cancer targets, scale up its customer network and expand pipelines to other types of cancers in dogs and cats. Financially, ImpriMed closed an $8m Pre-Series A round comprising $7.7m from venture capital investors and the remainder as a government grant. ImpriMed uses precision medicine techniques to test hundreds of drug responses on fresh biopsy samples from canine cancer patients, observing how live cancer cells react before treatment. The platform screens for the most effective chemotherapy options and excludes non-effective ones, then provides those results to veterinary oncologists. The company is currently focused on treating lymphoma in dogs. ImpriMed plans to roll out a clinical trial that will be performed primarily at SAGE Veterinary Centers in the Bay Area. For a limited time it is offering its service free of charge while completing the clinical trial and aims to help more than 500 dogs by 2020. The company was founded in 2017 and maintains an additional presence in Seoul, South Korea.